European CHMP recommends approval of apremilast for treatment of Behçet’s disease (BD)

The CHMP has recommended approval of this additional indication for apremilast, specifically for the treatment of adults with oral ulcers associated with BD who are candidates for systemic therapy. It is currently licensed for the treatment of psoriatic arthritis and psoriasis.

European Medicines Agency